← Back to Search

Interleukin-2 (IL-2) Agonist

Efavaleukin Alfa for Ulcerative Colitis

Phase 2
Waitlist Available
Research Sponsored by Amgen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 104

Summary

This trial will study the long-term safety of a drug for people with moderate to severe ulcerative colitis.

Who is the study for?
This trial is for people with moderate to severe ulcerative colitis who finished a previous phase 2 study and might benefit from more treatment. They must be able to follow the study plan and not have any other health issues that could interfere or pose a risk. Pregnant women, those planning pregnancy, or breastfeeding are excluded, as well as anyone with certain infections or cancer diagnosed in the earlier study.
What is being tested?
The trial tests the long-term safety of Efavaleukin Alfa in treating ulcerative colitis compared to a placebo. Participants previously involved in an initial dose-finding study will continue treatment to see how well they tolerate it over time and if it remains effective.
What are the potential side effects?
While specific side effects aren't listed here, participants will monitor for any adverse reactions due to Efavaleukin Alfa use over an extended period. This includes watching out for new symptoms or changes in their condition related to the drug.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 104
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 104 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Number of Participants with Corticosteroid-free Remission

Side effects data

From 2022 Phase 1 trial • 32 Patients • NCT04987333
88%
Injection site erythema
25%
Nausea
25%
Headache
25%
Injection site pruritus
25%
Swelling
13%
Dizziness
13%
Nasal congestion
13%
Vision blurred
13%
Injection site pain
13%
Pain in extremity
13%
Injection site rash
13%
Rhinitis
13%
Pruritus
13%
Rash
100%
80%
60%
40%
20%
0%
Study treatment Arm
Group 4: Caucasian Participants - Efavaleukin Alfa (Dose Level 2)
Group 1: Chinese Participants - Efavaleukin Alfa (Dose Level 1)
Group 2: Chinese Participants - Efavaleukin Alfa (Dose Level 2)
Group 3: Japanese Participants -Efavaleukin Alfa (Dose Level 2)

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Efavaleukin Alfa Dose 3 (High Dose)Experimental Treatment1 Intervention
Participants who were receiving efavaleukin alfa dose 3 during the dose-finding study (study 20170104) that decided to continue onto this long-term extension study will continue to receive efavaleukin alfa dose 3.
Group II: Efavaleukin Alfa Dose 2 (Moderate Dose)Experimental Treatment1 Intervention
Participants who were receiving efavaleukin alfa dose 2 during the dose-finding study (study 20170104) that decided to continue onto this long-term extension study will continue to receive efavaleukin alfa dose 2.
Group III: Efavaleukin Alfa Dose 1 (Low Dose)Experimental Treatment1 Intervention
Participants who were receiving efavaleukin alfa dose 1 during the dose-finding study (study 20170104) that decided to continue onto this long-term extension study will continue to receive efavaleukin alfa dose 1.
Group IV: PlaceboPlacebo Group1 Intervention
Participants who were receiving the placebo during the dose-finding study (study 20170104) that decided to continue onto this long-term extension study will continue to receive the placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Efavaleukin alfa
2021
Completed Phase 1
~40

Find a Location

Who is running the clinical trial?

AmgenLead Sponsor
1,431 Previous Clinical Trials
1,385,140 Total Patients Enrolled
5 Trials studying Colitis
868 Patients Enrolled for Colitis
MDStudy DirectorAmgen
970 Previous Clinical Trials
929,438 Total Patients Enrolled
5 Trials studying Colitis
868 Patients Enrolled for Colitis

Media Library

Efavaleukin alfa (Interleukin-2 (IL-2) Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT05672199 — Phase 2
Colitis Research Study Groups: Placebo, Efavaleukin Alfa Dose 1 (Low Dose), Efavaleukin Alfa Dose 2 (Moderate Dose), Efavaleukin Alfa Dose 3 (High Dose)
Colitis Clinical Trial 2023: Efavaleukin alfa Highlights & Side Effects. Trial Name: NCT05672199 — Phase 2
Efavaleukin alfa (Interleukin-2 (IL-2) Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05672199 — Phase 2
~10 spots leftby Nov 2025